| Enhancing clinical development through multinational trial and high-complexity regulatory expertise
JNPMEDI has appointed Sangmi Park as Executive Director to enhance its multinational clinical project capabilities and regulatory execution capacity.
Park, a graduate of Sookmyung Women’s University College of Pharmacy, brings over 25 years of experience from global pharmaceutical companies and CROs, including Gilead Sciences and Novartis. Her expertise spans clinical operations, data management, regulatory strategy, quality management, and pharmacovigilance.
She has led complex global programs across the U.S., Australia, Japan, China, and Europe, covering Pre-IND through global Phase III and Pre-NDA stages. Park has supported approvals for First-in-Class and orphan drugs, managed clinical programs for both drugs and medical devices, and successfully completed inspections by the MFDS, FDA, and EMA.
In her new role, Park will oversee global clinical strategy, operations, regulatory engagement, and quality management at JNPMEDI. Her appointment is expected to strengthen the company’s ability to execute high-complexity clinical programs and accelerate client drug development and market entry.
JNPMEDI CEO Kwunho Jeong stated, “Executive Director Park’s extensive experience in global clinical development and regulatory execution will significantly support our clients’ global goals and enhance our overall clinical capabilities.”
| Enhancing clinical development through multinational trial and high-complexity regulatory expertise
JNPMEDI has appointed Sangmi Park as Executive Director to enhance its multinational clinical project capabilities and regulatory execution capacity.
Park, a graduate of Sookmyung Women’s University College of Pharmacy, brings over 25 years of experience from global pharmaceutical companies and CROs, including Gilead Sciences and Novartis. Her expertise spans clinical operations, data management, regulatory strategy, quality management, and pharmacovigilance.
She has led complex global programs across the U.S., Australia, Japan, China, and Europe, covering Pre-IND through global Phase III and Pre-NDA stages. Park has supported approvals for First-in-Class and orphan drugs, managed clinical programs for both drugs and medical devices, and successfully completed inspections by the MFDS, FDA, and EMA.
In her new role, Park will oversee global clinical strategy, operations, regulatory engagement, and quality management at JNPMEDI. Her appointment is expected to strengthen the company’s ability to execute high-complexity clinical programs and accelerate client drug development and market entry.
JNPMEDI CEO Kwunho Jeong stated, “Executive Director Park’s extensive experience in global clinical development and regulatory execution will significantly support our clients’ global goals and enhance our overall clinical capabilities.”